Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.
作者信息
McHugh S M, Rowland T L
机构信息
Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, UK.
出版信息
Clin Exp Immunol. 1997 Nov;110(2):151-4. doi: 10.1111/j.1365-2249.1997.tb08310.x.
Abstract
摘要
相似文献
1
Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.
Clin Exp Immunol. 1997 Nov;110(2):151-4. doi: 10.1111/j.1365-2249.1997.tb08310.x.
2
Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone.
Immunol Lett. 1999 Jun 1;68(2-3):325-32. doi: 10.1016/s0165-2478(99)00055-3.
3
Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.
Clin Immunol Immunopathol. 1996 Dec;81(3):219-23. doi: 10.1006/clin.1996.0181.
4
Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester.
J Immunol. 2002 Mar 15;168(6):2644-51. doi: 10.4049/jimmunol.168.6.2644.
5
Thalidomide analogs from diamines: Synthesis and evaluation as inhibitors of TNF-alpha production.
Chem Pharm Bull (Tokyo). 2007 Feb;55(2):223-6. doi: 10.1248/cpb.55.223.
6
Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression.
Innate Immun. 2009 Feb;15(1):33-41. doi: 10.1177/1753425908099317.
7
Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB.
Pathobiology. 2006;73(2):82-92. doi: 10.1159/000094492.
8
Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells.
Immunopharmacology. 1998 Jul;40(1):11-20. doi: 10.1016/s0162-3109(98)00010-1.
9
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.
J Immunol. 1998 Oct 15;161(8):4236-43.
10
Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.
World J Gastroenterol. 2007 Apr 21;13(15):2166-73. doi: 10.3748/wjg.v13.i15.2166.
引用本文的文献
1
A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis.
Dermatol Ther (Heidelb). 2016 Sep;6(3):397-411. doi: 10.1007/s13555-016-0122-9. Epub 2016 Jun 11.
2
Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.
Clin Rheumatol. 2016 Jun;35(6):1521-7. doi: 10.1007/s10067-016-3256-3. Epub 2016 Apr 21.
3
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.
Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi: 10.1007/s00280-012-2040-6. Epub 2012 Dec 1.
4
The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.
J Palliat Med. 2012 Oct;15(10):1059-64. doi: 10.1089/jpm.2012.0146. Epub 2012 Aug 10.
5
Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
Xenobiotica. 2011 Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23.
6
Transport of thalidomide by the human intestinal caco-2 monolayers.
Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1-2):49-61. doi: 10.1007/BF03226408.
7
Thalidomide in gastrointestinal disorders.
Drugs. 2001;61(6):777-87. doi: 10.2165/00003495-200161060-00006.
8
Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro.
Clin Exp Immunol. 2000 Sep;121(3):472-9. doi: 10.1046/j.1365-2249.2000.01332.x.
9
Anti-TNF antibody treatment of Crohn's disease.
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I114-20. doi: 10.1136/ard.58.2008.i114.
本文引用的文献
1
THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS.
Clin Pharmacol Ther. 1965 May-Jun;6:303-6. doi: 10.1002/cpt196563303.
2
Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells.
Immunopharmacology. 1998 Jul;40(1):11-20. doi: 10.1016/s0162-3109(98)00010-1.
3
Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift.
Clin Exp Immunol. 1997 Jun;108(3):428-31. doi: 10.1046/j.1365-2249.1997.3781274.x.
4
Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.
Clin Immunol Immunopathol. 1996 Dec;81(3):219-23. doi: 10.1006/clin.1996.0181.
5
Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues.
Chirality. 1996;8(5):390-6. doi: 10.1002/(SICI)1520-636X(1996)8:5<390::AID-CHIR6>3.0.CO;2-I.
6
Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis.
Cytokine Growth Factor Rev. 1996 Aug;7(2):175-90. doi: 10.1016/1359-6101(96)00020-2.
7
Treatment of colitis in Behçet's disease with thalidomide.
Eur J Gastroenterol Hepatol. 1996 Sep;8(9):929-31.
8
Benzylphthalimides and phenethylphthalimides with thalidomide-like activity on the production of tumor necrosis factor alpha.
Biol Pharm Bull. 1995 Sep;18(9):1228-33. doi: 10.1248/bpb.18.1228.
9
Augmentation by phthalimides of phorbol ester-induced expression of tumor necrosis factor alpha message.
Biol Pharm Bull. 1996 Jul;19(7):1001-3. doi: 10.1248/bpb.19.1001.
10
Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.
Mol Med. 1996 Jul;2(4):506-15.
Zotero 插件